This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Somatuline Depot, lanreotide acetate
Description: Lanreotide is a somatostatin analogue which inhibits the excess release of growth hormone and IGF-1.
Somatostatin is a peptide hormone that regulates the endocrine system and affects neurotransmission and cell proliferation via interaction with G-protein-coupled somatostatin receptors and inhibition of the release of numerous secondary hormones.
Ipsen and Teijin
In July 2003, Ipsen and Teijin enter into an agreement to development and market four Ipsen products in Japan and a Teijin's anti-gout agent, TMX-67 for the treatment of gout in Europe.
The four products from Ipsen are a Glucagon-like peptide-1 analogue (GLP-1, code name: BIM51077) for which Teijin has been granted co-exclusive rights in Japan, a type 2-receptor selective somatostatin analogue (SSTR-2, code name: BIM23190), a parathyroid hormone 1-34 fragment analogue (PTH, code name: BIM44058), and a sustained-release formulation of a somatostatin analogue (Somatuline Autogel), for which Teijin has been granted exclusive rights in Japan. Teijin will develop the analogues of GLP-1, SSTR-2, PTH and Somatuline Autogel as treatments for type II diabetes, diabetic retinopathy, severe osteoporosis, and acromegaly, respectively.
Ipsen and Tercica
In October 2006, Tercica entered into a worldwide strategic collaboration agreement in endocrinology...See full deal structure in Biomedtracker
Partners: Teijin Pharma Limited
Somatuline Autogel News
Additional information available to subscribers only: